Roswell Park Teams Bring Research on New Cancer Therapies and Prognostic Tools to ASCO 2019

BUFFALO, N.Y. — Several Roswell Park Comprehensive Cancer Center teams have been invited to present their own latest research or to share their expertise as discussion leaders at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO), to be held May 31 to June 4 in Chicago, Illinois. The theme of this year’s gathering — the world’s largest clinical cancer research meeting — is “Caring for Every Patient, Learning from Every Patient.”

“The ASCO Annual Meeting is probably the single most influential gathering of cancer researchers in the world in terms of its impact on the development of cancer treatments, and we are proud to bring our newest findings and conclusions to these important conversations,” says Marc Ernstoff, MD, the Katherine Anne Gioia Chair of Medicine at Roswell Park.  

Highlights of Roswell Park’s participation in ASCO 2019 are outlined below, including presentations of new research on treatments and prognostic strategies for colorectal cancer, brain cancer, lung cancer and multiple myeloma and speaking opportunities for Roswell Park senior leaders recognized as thought leaders in their areas of specialty. All locations listed are within the McCormick Place conference center.

SATURDAY, JUNE 1

Patrick Boland, MD, Assistant Professor of Oncology in the Department of Medicine/GI Center, is senior author on abstract 3032 (board 24), “A phase I study of the oral administration of irinotecan in combination with the potent P-glycoprotein (P-gp) inhibitor HM30181A,” to be presented Saturday, June 1, from 8 a.m. to 11 a.m. CDT in Hall A during the Developmental Therapeutics and Tumor Biology (Nonimmuno) poster session.

SUNDAY, JUNE 2

Kunle Odunsi, MD, PhD, FRCOG, FACOG, is a chair of the Clinical Science Symposium “Are We Hitting the Bull’s-eye With Targeted Therapy?,” to be presented Sunday, June 2, from 8 a.m. to 9:30 a.m. CDT in room S406 (Gynecologic Cancer track). Session details at https://iplanner.asco.org/am2019/#/session/13931.

Robert Fenstermaker, MD, Chair of Neurosurgery, is senior author and Michael Ciesielski, PhD, Assistant Professor of Neurosurgery, is presenting author on abstract 2016 (board 205), “SurVaxM with standard therapy in newly diagnosed glioblastoma: Phase II trial update,” to be presented Sunday, June 2, from 8 a.m. to 11 a.m. CDT in Hall A as part of the Central Nervous System Tumors poster session. This work will also be highlighted by first author Manmeet Ahluwalia, MD, of the Taussig Center Institute, Cleveland Clinic, Sunday, June 2, from 4:30 p.m. to 6 p.m. CDT in room S404 as part of a poster discussion session.

Maya Khalil, MD, Hematology-Oncology Fellow, is first author and Grace Dy, MD, Chief of Thoracic Oncology, is senior author on abstract 8521 (board 277), “The tumor microenvironment in EGFR-driven loco-regional lung adenocarcinoma can predict higher risk of recurrence,” to be presented Sunday, June 2, from 8 a.m. to 11 a.m. CDT in Hall A during the poster session Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers (Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers track).

Sunyoung Lee, MD, PhD, Hematology-Oncology Fellow, is first author on abstract 8544 (board 300), “Immune landscape of the tumor microenvironment to predict prognosis and DNA mutations in patients with lung adenocarcinoma,” to be presented Sunday, June 2, from 8 a.m. to 11 a.m. CDT in Hall A during the poster session Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers (Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers track).

Philip L. McCarthy, MD, Director of the Transplant & Cellular Therapy Center within the Department of Medicine, is discussant on “Something Old, Something New: Evolving Paradigms in Untreated Multiple Myeloma,” an oral abstract session to be presented Sunday, June 2, from 10:21 a.m. to 10:33 a.m. CDT in room E451 (Hematologic Malignancies—Plasma Cell Dyscrasia track). Session details at https://iplanner.asco.org/am2019/#/session/13896.

MONDAY, JUNE 3

Igor Puzanov, MD, MSci, FACP, Chief of Melanoma and Director of the Early Phase Clinical Trials Program, is senior author on abstract 9524 (board 95), “Progression-free survival (PFS) in unresectable melanoma patients (pts) treated with talimogene laherparepvec (T-VEC) versus granulocyte macrophage colony-stimulating factor (GM-CSF) in OPTiM,” to be presented Monday, June 3, from 1:15 p.m. to  4:15 p.m. CDT in Hall A during the Melanoma/Skin Cancers poster session.

Jens Hillengass, MD, PhD, Chief of Myeloma, is discussant on “There’s More Than Multiple Myeloma: Other Plasma Cell Dyscrasias,” a poster discussion session to be presented Monday, June 3, from 2:21 p.m. to 2:33 p.m. CDT in room E450 (Hematologic Malignancies—Plasma Cell Dyscrasia track). Session details at https://iplanner.asco.org/am2019/#/session/13884.

###

Roswell Park Comprehensive Cancer Center is a community united by the drive to eliminate cancer’s grip on humanity by unlocking its secrets through personalized approaches and unleashing the healing power of hope. Founded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. Learn more at www.roswellpark.org, or contact us at 1-800-ROSWELL (1-800-767-9355) or ASKRoswell@RoswellPark.org.